HealthQuill Acquisition
Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.
Drugs Medical Pharma

Regeneron to buy bankrupt 23andMe Holding assets for $256 million

HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe.

Read More
Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a drug to treat a genetic kidney disease called autosomal dominant polycystic kidney disease.
Drugs Health Pharma

Novartis buys Regulus for $1.7b to grab genetic kidney disease drug

HQ Team April 30, 2025: Switzerland’s pharmaceutical company, Novartis AG,  will acquire Regulus Therapeutics for about $1.7 billion to get access to a.

Read More
Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to add rare tumour therapies to its portfolio.
Drugs Medical Pharma

Merck to buy SpringWorks for $3.9b to add rare tumour medicines

HQ Team April 29, 2025: Germany’s Merck KGaA, is set to acquire biopharmaceutical company SpringWorks Therapeutics Inc. for $3.9 billion in cash to.

Read More
Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from Biogen Inc., for an undisclosed amount.
Drugs Medical Pharma

Organon & Co. buys biosimilar from Biogen for an undisclosed sum

HQ Team April 2, 2025: Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from.

Read More
Thermo Fisher Scientific to buy Solvemtum’s purification unit for $4.1 billion in cash
Drugs Medical Pharma

Thermo Fisher to buy Solventum’s filtration unit for $4.1 billion in cash

HQ Team March 1, 2025: Thermo Fisher Scientific Inc., will buy Solventum’s purification and filtration business for $4.1 billion in cash to support.

Read More
US-based private equity and advisory investment firm KKR & Co. Inc. will pay CVC Capital Partners $400 million to acquire a majority stake in India’s HealthCare Global Enterprises Ltd. (HCG).
Health Medical Pharma

KKR to acquire majority stake in India’s HCG for $400 million

US-based private equity and advisory investment firm KKR & Co. Inc. will pay CVC Capital Partners $400 million to acquire a majority stake.

Read More
FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing the Anglo-Swedish firm to gain access to an anaemia drug in the world’s most populated nation.
Drugs Health Pharma

AstraZeneca Plc buys China unit of FibroGen Inc for $160 million

HQ Team February 21, 2025: FibroGen Inc., a US-based pharmaceutical company, will sell its China subsidiary to AstraZeneca Plc. for $160 million, allowing.

Read More
Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to the Massachusetts-based firm.
Drugs Health Medical

Bain Capital to buy Japan’s Mitsubishi Tanabe Pharma for $3.3 billion

Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to.

Read More
Globus Medical, a US-based medical device company, will buy Nevro Corp. for $250 million in an all-cash deal.
Health Medical Pharma

Globus Medical Inc to buy US-based Nevro Corp for $250 million all cash

Globus Medical, a US-based medical device company, will buy Nevro Corp. for $250 million in an all-cash deal.

Read More
Zimmer Biomet Holdings, Inc., a US medical device maker, will acquire Paragon 28 Inc., for $1.1 billion to expand into musculoskeletal care, according to a company statement.
Health Medical Pharma

Zimmer Biomet to buy Paragon 28 for $1.1b to expand musculoskeletal care

Zimmer Biomet Holdings, Inc., a US medical device maker, will acquire Paragon 28 Inc., for $1.1 billion to expand into musculoskeletal care, according.

Read More